Skip to content

Study · Systematic review · 2021

3 results

Anti-diabetic drugs and weight loss in patients with type 2 diabetes.

Lazzaroni E, Ben Nasr M, Loretelli C, Pastore I, Plebani L, Lunati ME, Vallone L, Bolla AM, Rossi A, Montefusco L, Ippolito E, Berra C, D'Addio F, Zuccotti GV, Fiorina P

Pharmacological research22 Jul 2021Cited by 144 (Europe PMC)

PMID34302978 (opens in a new tab)DOI10.1016/j.phrs.2021.105782 (opens in a new tab)PepBankPUB-34302978
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, a systematic review found liraglutide gave strong weight loss, greater than 5% of initial weight.

    In plain wordsIn adults with type 2 diabetes, a review found liraglutide led to weight loss of more than 5% of starting weight.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss in type 2 diabetes
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight loss
    > 5%
    initial weight

    Source sentences

    Summary
    liraglutide, semaglutide and tirzepatide resulted in a strong weight loss (greater than 5%)
    1 context sentence
    Summary · context
    A systematic analysis of the literature on the effect of non-insulin glucose lowering drugs on weight loss in patients with type 2 diabetes was performed.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, a systematic review found semaglutide gave strong weight loss, greater than 5% of initial weight.

    In plain wordsIn adults with type 2 diabetes, a review found semaglutide led to weight loss of more than 5% of starting weight.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss in type 2 diabetes
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight loss
    > 5%
    initial weight

    Source sentences

    Summary
    liraglutide, semaglutide and tirzepatide resulted in a strong weight loss (greater than 5%)
    1 context sentence
    Summary · context
    A systematic analysis of the literature on the effect of non-insulin glucose lowering drugs on weight loss in patients with type 2 diabetes was performed.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, a systematic review found tirzepatide gave strong weight loss, greater than 5% of initial weight.

    In plain wordsIn adults with type 2 diabetes, a review found tirzepatide led to weight loss of more than 5% of starting weight.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWeight loss in type 2 diabetes
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight loss
    > 5%
    initial weight

    Source sentences

    Summary
    liraglutide, semaglutide and tirzepatide resulted in a strong weight loss (greater than 5%)
    1 context sentence
    Summary · context
    A systematic analysis of the literature on the effect of non-insulin glucose lowering drugs on weight loss in patients with type 2 diabetes was performed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Versions 2 to 3

    9 Oct 2026, 03:07 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.